Canadian urological association

McMaster Institute of Urology at St.

The Canadian Urological Association CUA does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website. For comments or information, email Corporate. Privacy Policy.

Canadian urological association

Federal government websites often end in. The site is secure. Prostate cancer remains the most commonly diagnosed non-cutaneous malignancy among Canadian men and is the third leading cause of cancer-related death. In , an estimated 21 men were diagnosed with prostate cancer and men died from the disease; 1 however, prostate cancer is a heterogeneous disease with a clinical course ranging from indolent to life-threatening. Identifying and treating men with clinically significant prostate cancer while avoiding the over-diagnosis and over-treatment of indolent disease remains a significant challenge. Several professional associations have developed guidelines on prostate cancer screening and early diagnosis, but there are conflicting recommendations on how best to approach these issues. With recent updates from several large, randomized, prospective trials, as well as the emergence of several new diagnostic tests, the Canadian Urological Association CUA has developed these evidence-based recommendations to guide clinicians on prostate cancer screening and early diagnosis for Canadian men. The aim of these recommendations is to provide guidance on the current best prostate cancer screening and early diagnosis practices and to provide information on new and emerging diagnostic modalities. In order to develop these recommendations, the following questions related to prostate cancer screening and diagnosis were defined, a priori, to guide the specific literature searches and evidence synthesis:. The aim of answering the first four questions is to provide guidance on prostate cancer screening in general. The aim of the fifth question is to provide information on additional available tests. Therefore, a different search strategy was used for these questions. For the first four questions, we employed a two-step approach in order to synthesize the best available evidence to develop these recommendations. First, recognizing that several other professional organizations have developed evidence-based guidelines on prostate cancer screening and diagnosis, a complete bibliographic review of existing guidelines on prostate cancer screening and diagnosis was performed.

Corresponding author. In addition, there is a prostate risk calculator that was developed using data from Canadian men. Br J Cancer.

Federal government websites often end in. The site is secure. As we exited the pandemic, healthcare within Canada was forced to take stock of the unmet clinical care needs and assign priorities to address those demands. In order to best assist our members and their patients as we faced the post-pandemic new world order, CUA leadership felt it important to obtain the most updated information on the current state of urology in Canada. To that end, a census was developed and circulated to the CUA membership. The intention was to collect data on membership demographics and practice patterns, as well as to better understand workforce and resource challenges across the country. Moreover, it was hoped that the information obtained could be used by the CUA in its advocacy efforts with licensing, accrediting bodies, and policymakers.

The Canadian Urological Association CUA does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website. For comments or information, email Corporate. Privacy Policy.

Canadian urological association

Federal government websites often end in. The site is secure. Preview improvements coming to the PMC website in October Learn More or Try it out now. Prostate cancer remains the most commonly diagnosed non-cutaneous malignancy among Canadian men and is the third leading cause of cancer-related death. In , an estimated 21 men were diagnosed with prostate cancer and men died from the disease; 1 however, prostate cancer is a heterogeneous disease with a clinical course ranging from indolent to life-threatening. Identifying and treating men with clinically significant prostate cancer while avoiding the over-diagnosis and over-treatment of indolent disease remains a significant challenge. Several professional associations have developed guidelines on prostate cancer screening and early diagnosis, but there are conflicting recommendations on how best to approach these issues. With recent updates from several large, randomized, prospective trials, as well as the emergence of several new diagnostic tests, the Canadian Urological Association CUA has developed these evidence-based recommendations to guide clinicians on prostate cancer screening and early diagnosis for Canadian men. The aim of these recommendations is to provide guidance on the current best prostate cancer screening and early diagnosis practices and to provide information on new and emerging diagnostic modalities.

Holsman healthcare

Eur Urol. Among the various regions, recruitment was most likely in British Columbia, the Prairies, and Quebec. The potential benefits and harms of PSA screening for men less than age 45 has not been prospectively studied; however, a recently published case-control study nested within the Physicians Health Study cohort identified that the risk of developing metastatic prostate cancer within 15 years among men in this age group was very low, even among men with PSA levels in the top decile. Adjunctive strategies for improving prostate cancer early diagnosis The past two decades have seen the development or evaluation of several potential adjunctive measures that may increase the benefits or reduce the harms associated with screening in addition to PSA. The complete listing of the desired specialty training required for general and specialty practices highlighted by region is displayed in Figure 4. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: Data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Upcoming Events. Early detection of prostate cancer: AUA guideline. Associated Data Supplementary Materials Supplementary Table 1 Prostate cancer screening guidelines by other organizations. Based on: — Low incidence of prostate cancer and prostate cancer mortality — Lack of evidence for benefit of screening in this age group — Evidence of harms. Demographic surveys of the CUA membership had previously been conducted in and , focusing primarily on workforce issues. As such, we understand that standard prostate biopsies will continue to play a role in the evaluation of Canadian men suspected of having prostate cancer while we advocate for increased mpMRI resources. Catheter use, July

Laurence H. In , CUAJ became a bimonthly publication. As of , articles have been published monthly, alternating between print and online-only versions print issues are available in February, April, June, August, October, and December; online-only issues are produced in January, March, May, July, September, and November.

MIS: minimally invasive surgery. Hassan Razvi; ac. Corporate Contributor 6. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: An independent replication. As such, the decision of whether or not to undergo prostate cancer screening is, and will likely remain, an individualized decision. Transrectal prostate ultrasonography: Variability of interpretation. J Nat Canc Inst. There were no significant differences observed for community vs. The aim of answering the first four questions is to provide guidance on prostate cancer screening in general. Correlation of minute 0.